/
MTVA
$1.43-$0.01 (-0.68%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
β
of holders' portfolios
13F filers
0
institutions
Market cap
$7.6M
5M shares
52-week range
$0.97 β $19.03
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-26.59
MetaVia Inc. Common Stock
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
www.metaviatx.com- Employees
- 8
- IPO / List date
- Aug 4, 2016
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds MTVA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MTVA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-12-05 | 1-for-11reverse |
Recent trades on TradeandTell
No one on the platform has traded MTVA yet.
